U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197645) titled 'Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain' on July 30.
Brief Summary: This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Bone Pain
Metastatic Bone Tumor
Bone Metastases in Subjects With Advanced Cancer
Intervention:
DRUG: 153Sm-DOTMP
TLX090-Tx will be administered as a single ascending intravenous dose to participants with at least 1 confirmed painful osteoblastic bone tumor that...